SAN DIEGO, Feb. 20, 2015 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) today announced that the
underwriters of its previously announced public offering have
exercised in full their option to purchase an additional 1,041,600
shares of Neurocrine's common stock at the public offering price of
$36.00 per share, less underwriting
discounts and commissions. As a result, the total number of
shares being sold in the public offering is 7,985,600 shares.
The closing of the sale of all the shares in the offering is
expected to occur on or about February 24,
2015, subject to customary closing conditions.
J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are
acting as joint book-running managers for this offering, Jefferies
LLC and Barclays Capital Inc. are acting as co-lead managers for
this offering and Cowen and Company, LLC and Nomura Securities
International, Inc. are acting as co-managers for this offering.
The securities described above are being offered by Neurocrine
pursuant to a shelf registration statement previously filed with
the Securities and Exchange Commission (the "SEC") on February 25, 2014, which became automatically
effective by rule of the SEC upon filing. A final prospectus
supplement and accompanying prospectus relating to the offering
have been filed with the SEC and are available on the SEC's website
at www.sec.gov. The offering is being conducted only by means of
the prospectus supplement and accompanying prospectus, copies of
which may be obtained (when available) from J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at 866-803-9204, or from Deutsche Bank Securities Inc.,
Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, or by phone at
1-800-503-4611, or by email at prospectus.CPDG@db.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders.
Neurocrine's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone (GnRH) antagonist for women's health
that is partnered with AbbVie Inc., and a wholly owned vesicular
monoamine transporter 2 (VMAT2) inhibitor for the treatment of
movement disorders. Neurocrine intends to maintain certain
commercial rights to its VMAT2 inhibitor and evolve into a
fully-integrated pharmaceutical company.
In addition to historical facts, this press release contains
forward-looking statements that involve a number of risks and
uncertainties such as those, among others, relating to Neurocrine's
expectations regarding the completion of its public offering. Among
the factors that could cause actual results to differ materially
from those indicated in the forward-looking statements are risks
and uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
offering, as well as risks and uncertainties associated with
Neurocrine's business and finances in general, and the other risks
described in Neurocrine's annual report on Form 10-K for the year
ended December 31, 2014. Neurocrine
undertakes no obligation to update the statements contained in this
press release after the date hereof.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-inc-announces-exercise-in-full-of-underwriters-option-to-purchase-additional-shares-300038948.html
SOURCE Neurocrine Biosciences, Inc.